# (MP61-06) The role of wearable devices and CPET in predicting major complications after radical cystectomy

Pramit Khetrapal<sup>1</sup>, Norman R. Williams<sup>1</sup>, Gareth Ambler<sup>1</sup>, Rachael Sarpong<sup>1</sup>, Muhammed Shamim Khan<sup>3</sup>, Relanie Tan<sup>1</sup>, Andrew Feber<sup>1</sup>, Simon Dixon<sup>1</sup>, Louise Goodwin<sup>2</sup>, John McGrath<sup>4</sup>, Edward Rowe<sup>5</sup>, Anthony Koupparis <sup>5</sup>, Chris Brew-Graves <sup>1</sup>, James W.F. Catto <sup>1,2</sup>, John D Kelly <sup>1</sup>

#### **Background & Introduction**

- Fitness trackers have gained popularity for use in healthcare
- As part of the intracorporeal <u>Robotic vs Open Cystectomy</u> (iROC) trial, 340 patients will be prospectively recruited in various high volume centres in the UK.
- CPET is used to risk-stratify patients undergoing radical cystectomy in participating centres
- There is some evidence that daily step-counts could be a surrogate for performance status

#### Aims & Objectives

- The aim of this study is to assess step-count data from a wrist worn device in assessing patient fitness prior to radical cystectomy
- Objectives:
- To compare CPET variables with step-count data to explore associations
- To assess if CPET and step-count data can predict postoperative major complications (CD≥3)

### Methods

- At baseline, patients consented for the iROC trial were approached to wear a fitness tracker (Misfit Shine 2) for 7 consecutive days and daily step counts collected
- At baseline, patients also underwent a CPET
- anaerobic threshold (AT) <11 or VE/VCO2 ≥33 were used as used as predictors for high risk of complications
- Patients were divided into two groups: Clavien-Dindo major (CD)  $\geq$ 3 or minor ( $\leq$ 2) within 90 days.
- Spearman Rho was used to explore associations between non-parametrically distributed variables.
- Groups were compared using Mann-Whitney-U for nonparametrically distributed variables.
- A log transformation was performed prior to logistic regression analysis.



■ CD≤2 ■ CD≥3 Figure 4: Baseline average step-count and maximum stepcount for patients who went on to have none or minor complications (CD $\leq$ 2) or major complications (CD $\geq$ 3).





	_		
	AT risk	VE/VCO <sub>2</sub> risk	CPET combined risk
hitney	300	245.5	108.5
W	966	1373.5	1486.5
	-3.09	-3.50	-4.01
Sig. (2-	0.001996	0.000472	0.000061

computed Baseline data for NAC status,

age, BMI and ECOG were collected

### Results

Variable	В	S.E	р	O.R.			
MSC	-3.7	1.819	0.042	0.025 (0.001-0.874)			
CPET risk	0.087	0.793	0.913	1.091 (0.231-5.161)			
NAC	0.388	0.699	0.579	1.474 (0.375-5.797)			
Age	0.060	0.047	0.201	1.062 (0.968-1.165)			
BMI	0.026	0.019	0.166	1.026 (0.989-1.065)			
ECOG	0.557	0.354	0.116	1.746 (0.872-3.495)			
MSC = Maximum step-count, CPET = Cardiopulmonary Exercise Testing, NAC =							
Neoadjuvant chemotherapy, BMI = Body Mass Index, ECOG = Eastern Cooperative							
Oncology Group performance status							

Table 2: Binary logistic regression for baseline variables in predicting 90-day major complications (CD $\geq$ 3)

### Conclusions

- patients
- health status
- following RC
- relationship in a larger cohort

## Acknowledgements



Mann-Whitney U test showed that grouping patients by have none or minor complications (CD≤2) or major complications (CD $\geq$ 3), maximum step counts (MSC) were significantly different in the two groups (z = 2.161, p = 0.031). Box and whisker plot shown in Figure 4.

Due to the low event rate for CD≥3 complications (n=10), univariate logistic regression was performed Of the baseline variables, only step-counts predicted major complications (p = 0.042, OR 0.025)

• Wearable devices are easy to use and well-accepted by

• They can provide real-time snapshots of patients'

While the sample size is limited, step-count data from fitness trackers correlate well with CPET variables, and outperform CPET and other baseline measures of physical fitness in predicting major complications

 $\rightarrow$  The iROC trial will recruit 340 patients, and step-counts will be collected on all patients to analyse this

> The Champniss Foundation



Medical Research Council